Cereno Scientific – executive interview

In this video, Soo Romanoff, healthcare managing director of Edison Group, interviews Sten Sörensen, CEO of Cereno Scientific, who discusses the company’s innovative product portfolio, targeting unmet needs in the cardiovascular diseases (CVD) space, and the key upcoming catalysts.

Cereno Scientific is a clinical-stage biotech focused on developing treatments for CVD using novel approaches. The company has an exciting pipeline of differentiated assets targeting unmet needs in CVD, with one clinical and two preclinical programmes. Lead candidate CS1 has an interesting mechanism of action (a histone deacetylase inhibitor (HDACi) showing epigenetic modulation properties) and promises disease-modifying properties in pulmonary arterial hypertension, a rare, debilitating and progressive condition with no curative therapies. With Phase II readouts expected in Q324, the company is approaching a significant period of inflection. The preclinical pipeline is led by CS014, a novel HDACi, initially targeting thrombosis (the leading cause of morbidity in CVD), but without increased risk of bleeding associated with currently available antithrombotics. With preclinical studies complete, the drug is set to enter the clinic in H124. The company’s other preclinical asset, CS585, is an IP agonist, currently under evaluation for different CVD indications, backed by encouraging preclinical evidence.